AMPA + kainate glutamate receptor modulation

Category: signaling

Overview

AMPA receptors carry the fast-glutamate excitatory current that underlies most synaptic transmission. Pharmacological enhancement (AMPAkines / positive allosteric modulators) is a long-standing nootropic + cognitive-enhancement target. Mechanism evidence is patchier than benzodiazepine-site GABA-A modulation but several molecules act here. Racetams (piracetam, aniracetam, oxiracetam, pramiracetam, phenylpiracetam, coluracetam, fasoracetam) — original piracetam (Giurgea 1972) coined the "nootropic" category; mechanism nominally AMPA-allosteric + cholinergic facilitation; modest clinical signal except for breath-holding spells + myoclonus. Sunifiram + idra-21 are research-stage AMPAkines. Noopept is a peptidic dipeptide claimed to be a more potent racetam-like agent with BDNF modulation. AMPA negative allosteric modulator perampanel — covered in CNS-1.

Organ Systems

• nervous

Pathway Steps

1. glutamate → ampa-positive-modulation — via allosteric site enhances opening kinetics without orthosteric activity. AMPA receptors mediate fast excitatory transmission, and positive allosteric modulators (“ampakines”) slow their desensitization/deactivation to enhance glutamatergic signaling without directly opening the channel. By amplifying physiological activity (and downstream BDNF), ampakines have been explored as cognitive enhancers and for opioid-induced respiratory depression.

Known Modulators

• piracetam (activator) — AMPA (modest allosteric) + cholinergic facilitation. original racetam (1964); Rx in many EU countries (myoclonus + breath-holding spells); marginal cognitive signal in clinical trials
• aniracetam (activator) — AMPA (allosteric positive). fat-soluble racetam; faster Tmax than piracetam; anxiolytic claim
• oxiracetam (activator) — AMPA (allosteric positive). piracetam analog; mild stimulant claim
• pramiracetam (activator) — cholinergic uptake enhancement. racetam with strong choline-uptake claim; memory + focus marketing
• phenylpiracetam (activator) — AMPA + DAT/NET inhibition. phenyl-substituted piracetam; stimulant-like; WADA-banned for athletes
• coluracetam (activator) — high-affinity choline uptake (HACU). racetam; choline transport activation; depression + anxiety claims; research-stage
• fasoracetam (activator) — mGlu group I activator. racetam; mGlu receptor target distinguishes from AMPAkines; failed Alzheimer's trial
• sunifiram (activator) — AMPA (positive allosteric, research-stage). ampakine research compound; piperazine; nootropic supplement market
• idra 21 (activator) — AMPA (positive allosteric, research-stage). AMPAkine research compound; cognition + memory animal studies; no human trials
• noopept (activator) — BDNF/NGF + AMPA + cholinergic. dipeptide; claimed 1000× piracetam potency; Russian Rx (mild cognitive impairment); cycloprolyl-glycine metabolite as proposed active
• prl 8 53 (activator) — choline + dopamine system. research compound; one published human pilot (Hansl 1978); poorly characterized
• nsi 189 (activator) — BDNF/neurogenesis (research). neurogenic; failed phase 3 depression trial 2017
• bromantane (activator) — dopaminergic + serotonergic (adamantane derivative). Russian psychostimulant + nootropic; WADA-banned; military-stress claim
• centrophenoxine (activator) — DMAE prodrug → CNS choline + lipofuscin reduction. cholinergic precursor; nootropic + anti-aging claim
• dmae (activator) — dimethylaminoethanol (choline precursor). DMAE; topical (skin firmness) + oral nootropic claims
• idebenone (activator) — synthetic CoQ + ETC (cross-link: ros pathway)
• hydrafinil (activator) — wake-promoting (modafinil analog). 9-fluorenol; investigational; not FDA-approved

References

• PMID 26843645
• PMID 11978816